Company profile
Ticker
SGMT
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
3-V Biosciences, Inc.
SEC CIK
Corporate docs
IRS number
205991472
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
18 Apr 24
DEFA14A
Additional proxy soliciting materials
18 Apr 24
DEF 14A
Definitive proxy
18 Apr 24
S-8
Registration of securities for employees
25 Mar 24
10-K
2023 FY
Annual report
25 Mar 24
8-K
Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates
25 Mar 24
8-K
Departure of Directors or Certain Officers
2 Feb 24
8-K
Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock
30 Jan 24
EFFECT
Notice of effectiveness
26 Jan 24
8-K
Results of Operations and Financial Condition
24 Jan 24
Latest ownership filings
4
Timothy P Walbert
3 Apr 24
4
Paul W. Hoelscher
3 Apr 24
3
Timothy P Walbert
3 Apr 24
3
Paul W. Hoelscher
3 Apr 24
4
David Happel
28 Mar 24
SC 13G/A
FMR LLC
11 Mar 24
SC 13G
NEW ENTERPRISE ASSOCIATES 13 LP
14 Feb 24
SC 13G
HILLHOUSE INVESTMENT MANAGEMENT, LTD.
14 Feb 24
SC 13G
BAKER BROS. ADVISORS LP
14 Feb 24
SC 13G
KPCB PANDEMIC & BIO DEFENSE FUND LLC
14 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | |||
---|---|---|---|---|---|---|
Cash on hand (at last report) | 101.84 mm | 101.84 mm | ||||
Cash burn (monthly) | (no burn) | 2.48 mm | ||||
Cash used (since last report) | n/a | 17.45 mm | ||||
Cash remaining | n/a | 84.39 mm | ||||
Runway (months of cash) | n/a | 34.0 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Apr 24 | Paul W. Hoelscher | Stock Option Series A Common Stock | Grant | Acquire A | No | No | 5.23 | 73,014 | 381.86 k | 73,014 |
1 Apr 24 | Timothy P Walbert | Stock Option Series A Common Stock | Grant | Acquire A | No | No | 5.23 | 73,014 | 381.86 k | 73,014 |
26 Mar 24 | David Happel | Series A Common Stock | Buy | Acquire P | No | No | 5.267 | 12,100 | 63.73 k | 639,200 |
News
Sagimet Biosciences Announces Completion Of Phase 1 Hepatic Impairment Study With FASN Inhibitor Denifanstat
27 Mar 24
Goldman Sachs Maintains Buy on Sagimet Biosciences, Lowers Price Target to $27
26 Mar 24
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
25 Mar 24
12 Health Care Stocks Moving In Monday's Intraday Session
25 Mar 24
Leerink Partners Initiates Coverage On Sagimet Biosciences with Outperform Rating, Announces Price Target of $26
25 Mar 24
Press releases
Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat
27 Mar 24
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors
25 Mar 24
Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates
25 Mar 24